anti-cd19 monoclonal antibodies: a new approach to lymphoma therapy
نویسندگان
چکیده
cd19 is expressed on b- lineage cells and follicular dendritic cells and plays a key role in b cell malignancies and autoimmune diseases. thus, it has been considered as potential target for several monoclonal antibodies (mabs). for decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. but, anti- cd19 mabs developed for treating cd19- positive lymphomas and autoimmune diseases would rank among the most novel area of research and development in the pharmaceutical industry. moreover, several anti- cd19 mabs are currently being tested in various clinical trials and this review provides an overview of the research accomplished so far.
منابع مشابه
Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating...
متن کاملAnti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy
CD19 is expressed on B- lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti- CD19 mAbs developed for treating...
متن کاملNovel CD20 monoclonal antibodies for lymphoma therapy
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin's lymphom...
متن کاملPotentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
To study the immunotherapeutic potential of monoclonal antibodies (mAbs) directed against the human pan-B-cell antigen CD19, a xenotransplantation model was developed in which the human Burkitt's cell line Daudi is s.c. transplanted into nude mice. IgG1, IgG2b, and IgG2a isotype variants of the anti-CD19 mAb (CLB-CD19) were tested for their capacity to inhibit the growth of 10 x 10(6) Daudi cel...
متن کاملNew monoclonal antibodies for non-Hodgkin's lymphoma.
The anti-CD20 rituximab represents the first widely available antibody for the treatment of cancer based on significant singleagent activity in indolent lymphoma [1]. In diffuse large B-cell lymphoma (DLBCL), the incorporation of rituximab with standard chemotherapy improves survival [2]. However, while it is clear that the use of rituximab has had a significant impact in improving outcomes in ...
متن کاملa new approach to credibility premium for zero-inflated poisson models for panel data
هدف اصلی از این تحقیق به دست آوردن و مقایسه حق بیمه باورمندی در مدل های شمارشی گزارش نشده برای داده های طولی می باشد. در این تحقیق حق بیمه های پبش گویی بر اساس توابع ضرر مربع خطا و نمایی محاسبه شده و با هم مقایسه می شود. تمایل به گرفتن پاداش و جایزه یکی از دلایل مهم برای گزارش ندادن تصادفات می باشد و افراد برای استفاده از تخفیف اغلب از گزارش تصادفات با هزینه پائین خودداری می کنند، در این تحقیق ...
15 صفحه اولمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
international journal of molecular and cellular medicineجلد ۴، شماره ۳، صفحات ۱۴۳-۱۵۱
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023